Software Maker SAP Becomes Europe's Largest Company

An anonymous reader quotes a report from Reuters: German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market capitalization on Monday. At 0900 GMT, SAP had a market cap of $340 billion, slightly more than Novo Nordisk, according to Reuters calculations using LSEG Workspace data. SAP is Europe's largest software maker, providing business application software used by companies for finance, sales, supply chain and other functions. Its shares have surged in recent years, in part due to optimism that its cloud business will be a major beneficiary of recent investment in generative artificial intelligence. While SAP shares are up 7% so far in 2025, underperforming the broader European STOXX 600 index, which is up 8.3% year-to-date, they have clocked a total return of 160% since the end of 2022, far outperforming the STOXX 600's 28%. In contrast, Novo Nordisk shares have underperformed the market in recent months after data from trials of its experimental next-generation obesity drug Cagrisema disappointed investors. Read more of this story at Slashdot.

Mar 25, 2025 - 04:36

Software Maker SAP Becomes Europe's Largest Company

An anonymous reader quotes a report from Reuters: German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market capitalization on Monday. At 0900 GMT, SAP had a market cap of $340 billion, slightly more than Novo Nordisk, according to Reuters calculations using LSEG Workspace data. SAP is Europe's largest software maker, providing business application software used by companies for finance, sales, supply chain and other functions. Its shares have surged in recent years, in part due to optimism that its cloud business will be a major beneficiary of recent investment in generative artificial intelligence. While SAP shares are up 7% so far in 2025, underperforming the broader European STOXX 600 index, which is up 8.3% year-to-date, they have clocked a total return of 160% since the end of 2022, far outperforming the STOXX 600's 28%. In contrast, Novo Nordisk shares have underperformed the market in recent months after data from trials of its experimental next-generation obesity drug Cagrisema disappointed investors.